To identify potentially druggable adhesion targets, we measured the levels of adhesion molecules known to have commercially available blocking agents—namely CD44, CXCR4, CD49d and E-selectin—and found all except E-selectin to be highly expressed on AML cells. Here, SELE is linked to acute myeloid leukemia.